Cargando…

CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint

BACKGROUND: CD38 belongs to the ribosyl cyclase family and is expressed on various hematological cells and involved in immunosuppression and tumor promotion. Although targeting CD38 antibodies has been approved for treatment of multiple myeloma, the function of CD38 in solid tumor, oral squamous cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Zhuang, He, Yijia, Fu, Yong, Zhu, Nisha, Zhao, Mengxiang, Song, Yuxian, Huang, Xiaofeng, Chen, Sheng, Yang, Yan, Zhang, Caihong, Hu, Qingang, Ni, Yanhong, Ding, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239289/ https://www.ncbi.nlm.nih.gov/pubmed/34211854 http://dx.doi.org/10.3389/fonc.2021.687430

Ejemplares similares

Functional Heterogeneity of Reelin in the Oral Squamous Cell Carcinoma Microenvironment
por: Zhang, Xinwen, et al.
Publicado: (2021)

Worst Pattern of Perineural Invasion Redefines the Spatial Localization of Nerves in Oral Squamous Cell Carcinoma
por: Fu, Yong, et al.
Publicado: (2021)

Lipid Droplet-Related PLIN2 in CD68(+) Tumor-Associated Macrophage of Oral Squamous Cell Carcinoma: Implications for Cancer Prognosis and Immunotherapy
por: He, Yijia, et al.
Publicado: (2022)

Asparagine Synthetase-Mediated l-Asparagine Metabolism Disorder Promotes the Perineural Invasion of Oral Squamous Cell Carcinoma
por: Fu, Yong, et al.
Publicado: (2021)

The Regulatory Role of Non-coding RNAs on Programmed Cell Death Four in Inflammation and Cancer
por: Zhao, Mengxiang, et al.
Publicado: (2019)

OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling
por: Ding, Liang, et al.
Publicado: (2022)

The KiSS-1/GPR54 system: Essential roles in physiological homeostasis and cancer biology
por: Zhu, Nisha, et al.
Publicado: (2020)

The Ratio of Preoperative Serum Biomarkers Predicts Prognosis in Patients With Oral Squamous Cell Carcinoma
por: Ding, Meng, et al.
Publicado: (2021)

Identification of Biological Functions and Prognostic Value of NNMT in Oral Squamous Cell Carcinoma
por: Zhang, Weixian, et al.
Publicado: (2022)

ITGB2-mediated metabolic switch in CAFs promotes OSCC proliferation by oxidation of NADH in mitochondrial oxidative phosphorylation system
por: Zhang, Xiaoxin, et al.
Publicado: (2020)

Ki-67 is an independent prognostic marker for the recurrence and relapse of oral squamous cell carcinoma
por: Jing, Yue, et al.
Publicado: (2019)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
por: Principe, Daniel R., et al.
Publicado: (2021)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer
por: Ding, Yi, et al.
Publicado: (2022)

Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma
por: Li, Qiang, et al.
Publicado: (2020)

CD38: A Significant Regulator of Macrophage Function
por: Li, Wentao, et al.
Publicado: (2022)

Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway
por: Wang, Yujia, et al.
Publicado: (2019)

Higher Ki67 expression in fibroblast like cells at invasive front indicates better clinical outcomes in oral squamous cell carcinoma patients
por: Jing, Yue, et al.
Publicado: (2018)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
por: Wang, Ye, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoints and Innovative Therapies in Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer
por: Zhuang, Yuan, et al.
Publicado: (2021)

Tensile force-induced PDGF-BB/PDGFRβ signals in periodontal ligament fibroblasts activate JAK2/STAT3 for orthodontic tooth movement
por: Jin, Yuqin, et al.
Publicado: (2020)

Metabolic Molecule PLA2G2D Is a Potential Prognostic Biomarker Correlating With Immune Cell Infiltration and the Expression of Immune Checkpoint Genes in Cervical Squamous Cell Carcinoma
por: Liu, Hong, et al.
Publicado: (2021)

Aberrant Expression Of PDCD4/eIF4A1 Signal Predicts Postoperative Recurrence For Early-Stage Oral Squamous Cell Carcinoma
por: Zhao, Mengxiang, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
por: Ma, Jiajia, et al.
Publicado: (2022)

Development and Validation of a Robust Immune Prognostic Signature for Head and Neck Squamous Cell Carcinoma
por: Qiu, Yu, et al.
Publicado: (2020)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis
por: Zhou, Quanwei, et al.
Publicado: (2020)

Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma
por: Sun, Yawei, et al.
Publicado: (2021)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms
por: Liu, Man, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_221qr160pf1avps9i7qbf5n5u3